What the Study Found (In Plain English)
Published in Acta diabetologica (2005), this randomized controlled trial evaluating human clinical outcomes investigated: Cardiovascular risk is determined by multiple risk factors, all of which greatly increase the chance of morbidity and mortality. Key clinical takeaway: The use of beta-blockers and lipid-lowering therapy, known to reduce mortality and morbidity, is also higher in ONTARGET/TRANSCEND.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Acta diabetologica, 2005-04-15; Randomized Controlled Trial; Rigor 88/100): The use of beta-blockers and lipid-lowering therapy, known to reduce mortality and morbidity, is also higher in ONTARGET/TRANSCEND.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.